Compare ZVRA & CBLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZVRA | CBLL |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | 280 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 741.9M | 750.1M |
| IPO Year | 2015 | N/A |
| Metric | ZVRA | CBLL |
|---|---|---|
| Price | $13.52 | $19.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $23.00 | ★ $23.20 |
| AVG Volume (30 Days) | ★ 1.9M | 287.2K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 159.21 | N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $106,470,000.00 | N/A |
| Revenue This Year | $37.27 | $29.57 |
| Revenue Next Year | $53.42 | $28.44 |
| P/E Ratio | $22.05 | ★ N/A |
| Revenue Growth | ★ 350.91 | N/A |
| 52 Week Low | $7.16 | $10.85 |
| 52 Week High | $14.27 | $24.33 |
| Indicator | ZVRA | CBLL |
|---|---|---|
| Relative Strength Index (RSI) | 65.58 | 61.45 |
| Support Level | $8.26 | $18.91 |
| Resistance Level | $14.27 | $21.51 |
| Average True Range (ATR) | 0.77 | 0.82 |
| MACD | 0.04 | 0.22 |
| Stochastic Oscillator | 78.86 | 74.80 |
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.